Author:
Harboe Zitta Barrella,Rezahosseini Omid,Fischer Thea K
Reference5 articles.
1. Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study;Falsey;Lancet Infect Dis,2024
2. Respiratory syncytial virus prefusion F protein vaccine in older adults;Papi;N Engl J Med,2023
3. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults;Walsh;N Engl J Med,2023
4. Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic;Bukan;Aging Clin Exp Res,2023
5. Early safety findings among persons aged ≥60 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024;Hause;MMWR Morb Mortal Wkly Rep,2024